预测嗜铬细胞瘤与副神经节瘤转移潜能:PASS与GAPP评分系统的比较
本研究回顾性分析143例嗜铬细胞瘤(PCC)或副神经节瘤(PGL)患者,评估PASS和GAPP评分系统预测转移的能力及其与生存结局的相关性。结果显示GAPP评分较高与侵袭性PCC/PGL相关,而PASS评分与转移无关且观察者间变异显著。
要点
- GAPP评分较高与PCC/PGL侵袭性及复发风险增加相关。
- PASS评分与转移无显著关联,且观察者间一致性较低。
- SDHB胚系致病性变异、肾上腺外肿瘤、Ki-67指数1%-3%与无复发生存期缩短相关。
核心结论
- 较高的GAPP评分与侵袭性PCC/PGL相关。
- PASS评分与转移无关,且存在显著的观察者间变异。
- 预测PCC/PGL转移的评分系统可能通过整合组织病理学、临床数据及胚系和体细胞肿瘤标志物而改进。
研究设计与样本
- 回顾性队列研究,纳入143例PCC/PGL患者,其中PCC 106例,PGL 37例。
- 纳入标准为随访≥5年或已知转移。
- 重新审阅手术病理切片并分配PASS和GAPP评分。
- 采用单变量和多变量逻辑回归、Kaplan-Meier生存分析及Cox比例风险模型评估无复发生存期(RFS)和疾病特异性生存期(DSS)。
主要发现
- 24%的患者发生转移。
- PASS评分中位数为6.5(IQR 4.0-8.0),GAPP评分中位数为3.0(IQR 2.0-4.0)。
- PASS的观察者间信度低至中等(ICC 0.6082),GAPP的信度良好(ICC 0.7921)。
临床怎么用
- 在评估PCC/PGL转移风险时,GAPP评分可能优于PASS评分。
- 应考虑整合SDHB胚系变异、肾上腺外位置和Ki-67指数等临床病理特征。
- PASS评分因观察者间一致性较低,单独用于预测转移需谨慎。
局限性
- 回顾性研究设计。
- 样本量有限(143例)。
- 未报告其他潜在混杂因素的调整情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) and the Grading System for Adrenal Pheochromocytoma and Paraganglioma (GAPP) are scoring systems to predict metastatic potential in pheochromocytomas (PCC) and paragangliomas (PGLs). The goal of this study is to assess PASS and GAPP as metastatic predictors and to correlate with survival outcomes. METHODS: The cohort included PCC/PGL with ≥5 years of follow-up or known metastases. Surgical pathology slides were rereviewed. PASS and GAPP scores were assigned. Univariable and multivariable logistic regression, Kaplan-Meier survival analysis, and Cox proportional hazards were performed to assess recurrence-free survival (RFS) and disease-specific survival (DSS). RESULTS: From 143 subjects, 106 tumors were PCC and 37 were PGL. Metastases developed in 24%. The median PASS score was 6.5 (interquartile range [IQR]: 4.0-8.0) and median GAPP score was 3.0 (IQR: 2.0-4.0). Interrater reliability was low-moderate for PASS (intraclass correlation coefficient [ICC]: 0.6082) and good for GAPP (ICC 0.7921). Older age (OR: 0.969, P = .0170) was associated with longer RFS. SDHB germline pathogenic variant (OR: 8.205, P = .0049), extra-adrenal tumor (OR: 6.357, P < .0001), Ki-67 index 1% to 3% (OR: 4.810, P = .0477), and higher GAPP score (OR: 1.537, P = .0047) were associated with shorter RFS. PASS score was not associated with RFS (P = .1779). On Cox regression, a GAPP score in the moderately differentiated range was significantly associated with disease recurrence (HR: 3.367, P = .0184) compared with well-differentiated score. CONCLUSION: Higher GAPP scores were associated with aggressive PCC/PGL. PASS score was not associated with metastases and demonstrated significant interobserver variability. Scoring systems for predicting metastatic PCC/PGL may be improved by incorporation of histopathology, clinical data, and germline and somatic tumor markers.
引用
- Wachtel H, Hutchens T, Baraban E, et al. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. J Clin Endocrinol Metab. 2020. PMID: 32877928. doi:10.1210/clinem/dgaa608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。